Skip to main content

Lyumjev Side Effects

Generic name: insulin lispro

Medically reviewed by Philip Thornton, DipPharm. Last updated on Aug 29, 2023.

Note: This document contains side effect information about insulin lispro. Some dosage forms listed on this page may not apply to the brand name Lyumjev.

Applies to insulin lispro: solution.

Serious side effects of Lyumjev

Along with its needed effects, insulin lispro (the active ingredient contained in Lyumjev) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking insulin lispro:

More common

Less common


Incidence not known

Other side effects of Lyumjev

Some side effects of insulin lispro may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to insulin lispro: injectable solution, subcutaneous solution.


Adverse reactions observed have included hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.[Ref]


Very common (10% or more): Hypoglycemia

Frequency not reported: Weight gain[Ref]

Weight gain has been reported with insulin therapy and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.[Ref]


Frequency not reported: Allergic reactions including anaphylaxis[Ref]

Hypersensitivity side effects have included both local and systemic reactions. Anaphylaxis has been reported. Local reactions have presented as erythema, local edema, and pruritus at the injection site. Most minor reactions to insulin at the injection site resolve in a few days to a few weeks.

Generalized allergy to insulin may present as a whole body rash, dyspnea, wheezing, hypotension, tachycardia, or diaphoresis. In clinical trials, pruritus (with or without rash) was seen in 17 patients receiving human insulin (n=2969) and 30 patients receiving insulin lispro (n=2944).[Ref]


Common (1% to 10%): Infusion site reactions

Rare (less than 0.1%): Catheter occlusions/month[Ref]


Rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder and worsening of diabetic retinopathy. However, long-term glycemic control decreases the risk of diabetic retinopathy.[Ref]

Uncommon (0.1% to 1%): Refraction disorder, worsening of diabetic retinopathy[Ref]

Nervous system

Rapid improvement in glucose control has been associated with a transitory, reversible acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk.[Ref]

Very common (10% or more): Headache (up to 29.6%)

Rare (less than 0.1%): Painful peripheral neuropathy[Ref]


Very common (10% or more): Flu syndrome (up to 34.6%), infection (up to 13.6%)

Frequency not reported: Anti-insulin antibody titers[Ref]

The clinical significance of the development of these antibody titers is unknown.[Ref]


Insulin may cause sodium retention and edema, especially as metabolic control is improving.[Ref]

Frequency not reported: Peripheral edema[Ref]


Long-term use of insulin may cause lipodystrophy at the site of repeated injection. Lipodystrophy includes lipohypertrophy, a thickening of adipose tissue, and lipoatrophy, thinning of adipose tissue.[Ref]

Uncommon (0.1% to 1%): Urticaria, rash

Frequency not reported: Lipodystrophy including lipohypertrophy and lipoatrophy[Ref]


Common (1% to 10%): Nausea, diarrhea, abdominal pain[Ref]


Common (1% to 10%): Urinary tract infection, dysmenorrhea[Ref]


Common (1% to 10%): Myalgia[Ref]


Very common (10% or more): Pain (up to 19.8%)

Common (1% to 10%): Fever[Ref]


Very common (10% or more): Pharyngitis (up to 33.3%), rhinitis (up to 24.7%), increased cough (up to 17.3%)

Common (1% to 10%): Sinusitis, bronchitis[Ref]

Frequently asked questions


1. (2002) "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company

2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.